Browse TACR2

Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance K > neuromedin-K > substance P.

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0001956 positive regulation of neurotransmitter secretion
GO:0002790 peptide secretion
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006836 neurotransmitter transport
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006939 smooth muscle contraction
GO:0006940 regulation of smooth muscle contraction
GO:0007217 tachykinin receptor signaling pathway
GO:0007269 neurotransmitter secretion
GO:0007271 synaptic transmission, cholinergic
GO:0007588 excretion
GO:0007611 learning or memory
GO:0007612 learning
GO:0008015 blood circulation
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0014055 acetylcholine secretion, neurotransmission
GO:0014056 regulation of acetylcholine secretion, neurotransmission
GO:0014057 positive regulation of acetylcholine secretion, neurotransmission
GO:0014821 phasic smooth muscle contraction
GO:0014827 intestine smooth muscle contraction
GO:0014831 gastro-intestinal system smooth muscle contraction
GO:0015696 ammonium transport
GO:0015833 peptide transport
GO:0015837 amine transport
GO:0015870 acetylcholine transport
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0032222 regulation of synaptic transmission, cholinergic
GO:0032224 positive regulation of synaptic transmission, cholinergic
GO:0032274 gonadotropin secretion
GO:0032275 luteinizing hormone secretion
GO:0032276 regulation of gonadotropin secretion
GO:0032277 negative regulation of gonadotropin secretion
GO:0033684 regulation of luteinizing hormone secretion
GO:0033685 negative regulation of luteinizing hormone secretion
GO:0035106 operant conditioning
GO:0042886 amide transport
GO:0043114 regulation of vascular permeability
GO:0043117 positive regulation of vascular permeability
GO:0043270 positive regulation of ion transport
GO:0044057 regulation of system process
GO:0044060 regulation of endocrine process
GO:0044708 single-organism behavior
GO:0045933 positive regulation of muscle contraction
GO:0045987 positive regulation of smooth muscle contraction
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0046928 regulation of neurotransmitter secretion
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050886 endocrine process
GO:0050890 cognition
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051588 regulation of neurotransmitter transport
GO:0051590 positive regulation of neurotransmitter transport
GO:0051602 response to electrical stimulus
GO:0051952 regulation of amine transport
GO:0051954 positive regulation of amine transport
GO:0060986 endocrine hormone secretion
GO:0061526 acetylcholine secretion
GO:0070459 prolactin secretion
GO:0070471 uterine smooth muscle contraction
GO:0070472 regulation of uterine smooth muscle contraction
GO:0070474 positive regulation of uterine smooth muscle contraction
GO:0090257 regulation of muscle system process
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1901374 acetate ester transport
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
Molecular Function GO:0001653 peptide receptor activity
GO:0004995 tachykinin receptor activity
GO:0008188 neuropeptide receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016497 substance K receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-380095: Tachykinin receptors bind tachykinins
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TACR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TACR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Resistant to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TACR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0820.758
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1490.744
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2430.531
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3710.521
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5470.741
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1620.927
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5790.135
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2180.725
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.5050.0199
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1390.795
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2190.762
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2160.43
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TACR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TACR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TACR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TACR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TACR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TACR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TACR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTACR2
Nametachykinin receptor 2
Aliases SKR; NK2R; TAC2R; NKNAR; NK-2 receptor; NK-2R; neurokinin 2 receptor; neurokinin A receptor; substance K rec ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TACR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TACR2.
ID Name Drug Type Targets #Targets
DB06660SaredutantSmall MoleculeTACR21